A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Recruiting · Phase 2 · NCT07276997
Conditions: Major Depressive Disorder
At a glance
- Research payments reported, 2025
- $84,571
- U.S. investigators named
- 6
- Sites paid
- 5
- Planned or actual enrollment
- 195
About the trial
- Sponsor
- AbbVie
- Tested
- Icalcaprant (drug), Placebo for Icalcaprant (drug)
- Dates
- Started 2025-12-18; completion 2027-09
- Results posted
- Not yet
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major d…
From ClinicalTrials.gov, last updated 2026-06-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $84,571 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Iman Parhami, M.D., MPH Psychiatry · Woodland Hills, CA
- Charmaine I. Semeniuk, M.D. Psychiatry · San Diego, CA
- Leonardo Alonso, M.D. Psychiatry · Miami, FL
- Edwin A. Gomez, M.D. Psychiatry · Weston, FL
- Guy E. Brannon, M.D. Psychiatry · Shreveport, LA
- Eli Shalenberg, M.D. Student in an Organized Health Care Education/Training Program · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cenexel Clinical Research Inc $23,064
- Im Super Holdings LLC $18,875
- Qcare Site Services Inc $18,000
- Erg Clinical Research California PC $13,532
- Global Medical Institutes $11,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.